Oncopharmpod

Repotrectinib & Capivasertib

FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.

Unlimited access to all content on the platform.
More than 30 thousand titles, including audiobooks, ebooks, podcasts, series and documentaries.
Narration of audiobooks by professionals, including actors, announcers and even the authors themselves.

Try it Now Firm without compromise. Cancel whenever you want.